Insulin resistance, ADMA levels, and cardiovascular disease

JAMA

Volumn 287, Issue 11, 2002, Pages 1451-1452

  Nash, David T ^a  

^a Syracuse Preventive Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; ROSIGLITAZONE;

BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; ENDOTHELIUM; ENZYME ACTIVITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0037139436     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.11.1451     Document Type: Editorial

References (20)

1. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor
2. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine
3. Does ADMA cause endothelial dysfunction?
4. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells
5. Novel mechanism for endothelial dysfunction, dysregulation of dimethylarginine dimethylaminohydrolase
6. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase
7. Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine
8. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes
9. The role of the endothelium in cardiovascular homeostasis and disease
10. Risk of acute coronary events and serum concentrations of asymmetrical dimethylarginine
11. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects
12. Prevalence of the metabolic syndrome among US adults
13. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
14. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels
15. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
16. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion
17. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects
18. Thiazolidinediones, peroxisome proliferatoractivated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides
19. Endothelial dysfunction: Why it belongs in general practice